Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis (LN) Treated With KYV-101

KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed

EMERYVILLE, Calif., Nov. 14, 2024 /PRNewswire/ — Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announces today that it will present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase 1/2 studies and named patient treatments.

The latest data shows that patients with severe Lupus Nephritis (LN) who were treated with KYV-101 have experienced positive sustained efficacy and durability at a greater than six-month follow-up period. This is promising news for those suffering from this debilitating autoimmune disease, as finding effective treatments for LN can be challenging.

In addition to the positive efficacy results, KYV-101 continues to demonstrate robust safety and tolerability in patients. Importantly, no high-grade Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) were observed in the study participants. This is a significant finding as these side effects can be severe and potentially life-threatening in cell therapy treatments.

The ongoing studies, KYSA-1 and KYSA-3, along with named patient treatments, provide valuable insights into the potential of KYV-101 as a promising treatment option for patients with severe Lupus Nephritis. These results bring hope to those affected by LN and highlight the importance of continued research and development in the field of autoimmune diseases.

How Will This Affect Me?

If you are a patient suffering from severe Lupus Nephritis, the positive results of KYV-101 treatment offer hope for improved outcomes and a potential new treatment option. It is important to discuss these findings with your healthcare provider to determine if KYV-101 may be a suitable treatment option for you.

How Will This Affect the World?

The positive outcomes of KYV-101 treatment in patients with severe Lupus Nephritis have the potential to significantly impact the field of autoimmune diseases. If KYV-101 continues to show efficacy and safety in larger studies, it could become a game-changing treatment option for patients worldwide, offering new hope for those battling autoimmune conditions.

Conclusion

The latest data from Kyverna Therapeutics, Inc. on the efficacy and safety of KYV-101 in patients with severe Lupus Nephritis is a promising development in the field of autoimmune diseases. These results offer hope for improved outcomes and new treatment options for those affected by LN, and pave the way for advancements in the treatment of autoimmune conditions on a global scale.